Introduction: The efficacy of anti-TNFα agents has been recently evaluated in many studies
in Behçet's disease (BD), particularly in ocular and life-threatening manifestations such as …

Purpose: Anti-tumour necrosis factor-alpha (TNF-α) agents are often used for Behçet's
disease (BD) in clinical practice, but they have not been validated by a high level of …

Objective. The aim of this study was to assess the efficacy of anti-TNF-α therapy in refractory
uveitis due to Behçet's disease (BD). Methods. We performed a multicentre study of 124 …

Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD),
which tends to respond poorly to different medications. The ocular histopathologic changes …

Introduction Behçet's disease (BD) associated uveitis occurs in approximately 50–70% of
the patients. Ocular involvement in BD may induce a severe affection of visual function …

Objective. Despite the remarkable efficacy of anti-TNF agents in Behçet's disease (BD),
unmet therapeutic needs for refractory or intolerant patients to these drugs still exist. Based …

Behcet's disease (BD) is a multisystem, chronic-relapsing, inflammatory disorder classified
among the vasculitides [1, 2]. It has a worldwide distribution being more prevalent in the …

To identify clinical variables capable of predicting long-term treatment duration of TNF-α
inhibition in patients with Behçet's disease (BD)-related uveitis. Demographic, clinical, and …

Objective. Initial recommendations on anti-TNF treatment for Behçet's disease (BD) included
an intravenous infliximab infusion for acute posterior uveitis to achieve a fast-onset …

Purpose To evaluate the long-term efficacy and safety of infliximab for the treatment of
uveitis in Behçet's disease (BD). Design Retrospective multicenter study using a …